| White Energy Company Limited (WEC) ORDINARY FULLY PAID |
Energy |
$11 |
Proposed issue of securities - WEC
|
26 Feb 2025 9:14AM |
$0.028 |
$0.035 |
risen by
25%
|
|
| Cettire Limited (CTT) ORDINARY FULLY PAID |
Consumer Discretionary |
$114 |
H1 FY25 Results Presentation
|
26 Feb 2025 9:13AM |
$1.175 |
$0.300 |
fallen by
74.47%
|
|
CTT - Price-sensitive ASX Announcement
Full Release
Key Points
- Cettire reported a 12% increase in gross revenue to $514.1 million in H1 FY25.
- Sales revenue increased by 11% to $394 million in H1 FY25 compared to H1 FY24.
- Active customers grew by 21% to 695,000 in H1 FY25.
- Gross revenues from repeat customers increased by 29% year-on-year.
- Cettire maintained a net cash position of $101 million with zero debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Helloworld Travel Limited (HLO) ORDINARY FULLY PAID |
Consumer Discretionary |
$219 |
HLO Appendix 4D Half Year 2025
|
26 Feb 2025 9:13AM |
$2.050 |
$1.340 |
fallen by
34.63%
|
|
HLO - Price-sensitive ASX Announcement
Full Release
Key Points
- Total transaction value decreased by 6.9% to $2,050 million.
- Total revenue and other income fell by 7.6% to $103.8 million.
- Underlying EBITDA decreased by 20.2% to $27.2 million.
- Profit before income tax declined by 27.1% to $17.2 million.
- Profit after income tax attributable to shareholders decreased by 28.2% to $11.5 million.
- Basic and diluted earnings per share dropped by 29.7% to 7.1 cents.
- Interim dividend declared at 8.0 cents per share, a 60% increase from the previous year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$52 |
Appendix 4D & FY25 Interim Report
|
26 Feb 2025 9:13AM |
$0.240 |
$0.115 |
fallen by
52.08%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY25 revenue of $8.08 million, up 147% from the previous period.
- MetaXplore sales in Australia increased significantly, with 4,400 tests sold in H1 FY25.
- The net loss before income tax was $5.74 million, down 50% from the previous year.
- MAP 315 is advancing towards a Phase 2 clinical trial for Inflammatory Bowel Disease.
- The company has $17.3 million in cash and equivalents as of 31 December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NZME Limited (NZM) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Communication Services |
$197 |
Dividend/Distribution - NZM
|
26 Feb 2025 9:13AM |
$0.970 |
$1.050 |
risen by
8.25%
|
|
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$33 |
Presentation Half- Year Financial Report
|
26 Feb 2025 9:13AM |
$0.120 |
$0.115 |
fallen by
4.17%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- Balance sheet strengthened
- Completed a successful capital raise
- Global sales rose 39% in constant currency
- Sales growth was temporarily impacted by supply chain challenges
- Sales in January 2025 were approximately 25% higher than January 2024
- Glaucoma division expected to be profitable in H2 FY25
- Projected revenue of US$9 million to US$10 million in H2 FY25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$7,042 |
Notification of buy-back - WOR
|
26 Feb 2025 9:12AM |
$14.020 |
$13.310 |
fallen by
5.06%
|
|
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$33 |
Half-Year Report Release
|
26 Feb 2025 9:12AM |
$0.120 |
$0.115 |
fallen by
4.17%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of US$8.5 million, up 27% YoY.
- 12-month sales totalled US$16.9 million.
- Revenue guidance for H2 FY25 expected between US$9 million and US$10 million.
- Glaucoma division EBITDA loss of US$1.8 million.
- iTrack™ Advance driving sales growth.
- Strong surgeon adoption supported by marketing investments.
- A$6.6 million capital raise completed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$4,386 |
Change of Director's Interest Notice - D Goodin
|
26 Feb 2025 9:12AM |
$35.750 |
$30.050 |
fallen by
15.94%
|
|
| Aussie Broadband Limited (ABB) ORDINARY FULLY PAID |
Communication Services |
$1,145 |
Update - Notification of buy-back - ABB
|
26 Feb 2025 9:12AM |
$3.740 |
$3.995 |
risen by
6.82%
|
|
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$33 |
Half Yearly Report and Accounts
|
26 Feb 2025 9:12AM |
$0.120 |
$0.115 |
fallen by
4.17%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss after tax of $5,394,000 for the half-year ending December 31, 2024
- Improvement from previous year's loss of $5,625,000
- 27% increase in sales revenue to $12,925,000
- EBITDA loss of $4,237,000 compared to $4,190,000 in the prior period
- Growth driven by the Glaucoma Surgical Devices segment in the USA
- Challenges remain due to production cost increases and supply chain issues
- Company plans to raise $6.6 million through a share placement
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Maximus Resources Limited (MXR) ORDINARY FULLY PAID |
Materials |
$33 |
Change in substantial holding from AAR
|
26 Feb 2025 9:11AM |
$0.064 |
$0.077 |
risen by
20.31%
|
|
| Astral Resources NL (AAR) ORDINARY FULLY PAID |
Materials |
$241 |
Change in substantial holding for MXR
|
26 Feb 2025 9:11AM |
$0.135 |
$0.170 |
risen by
25.93%
|
|
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$4,790 |
Appendix 3Y - Wallis Graham
|
26 Feb 2025 9:11AM |
$5.830 |
$5.725 |
fallen by
1.80%
|
|
| Energy Resources of Australia Limited (ERA) ORDINARY FULLY PAID 'A' |
Energy |
$1,013 |
Preliminary Final Report
|
26 Feb 2025 9:11AM |
$0.002 |
$0.003 |
risen by
25%
|
|
ERA - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss after tax decreased to $246 million in 2024 from $1,388 million in 2023.
- Total cash and security receivables of $1,326 million as of 31 December 2024.
- No debt financing in place.
- Rehabilitation provision increased to $2,423 million.
- Ongoing rehabilitation activities at the Ranger Project Area.
- Non-renewal of Jabiluka Mineral Lease poses significant challenges.
- Additional funding required by 2027 to meet rehabilitation obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PPK Group Limited (PPK) ORDINARY FULLY PAID |
Materials |
$28 |
PPK Half Year results
|
26 Feb 2025 9:11AM |
$0.350 |
$0.305 |
fallen by
12.86%
|
|
| Paladin Energy Ltd (PDN) ORDINARY FULLY PAID |
Energy |
$2,906 |
December 2024 Half Year Financial Results Overview
|
26 Feb 2025 9:11AM |
$7.290 |
$7.285 |
fallen by
0.07%
|
|
| Lachlan Star Limited (LSA) ORDINARY FULLY PAID |
Materials |
$18 |
Significant Gold results highlight potential of Killaloe
|
26 Feb 2025 9:10AM |
$0.068 |
$0.073 |
risen by
7.35%
|
|
LSA - Price-sensitive ASX Announcement
Full Release
Key Points
- High-potential gold targets identified at Killaloe Project.
- Significant historical drilling results at the Duke prospect.
- Recent mapping confirmed extensive gold mineralisation.
- High-grade gold assays returned from rock chip and soil sampling.
- Drilling programs scheduled to commence in the coming months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$659 |
Update - Notification of buy-back - FPR
|
26 Feb 2025 9:10AM |
$2.520 |
$2.935 |
risen by
16.47%
|
|
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$513 |
Dividend/Distribution - ACL
|
26 Feb 2025 9:10AM |
$3.700 |
$2.610 |
fallen by
29.46%
|
|
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$513 |
1H25 financial results investor presentation
|
26 Feb 2025 9:09AM |
$3.700 |
$2.610 |
fallen by
29.46%
|
|
ACL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total Revenue of $369.2M, up $31.9M on 1H FY24
- Underlying EBIT of $27.3M in line with company expectations
- Statutory NPAT of $11.8M, up $6.8M on 1H FY24
- ACL's MBS revenue growth for 1H FY25 was 9.7%
- 2H FY25 revenue guidance reaffirmed at $725M to $752M
- Interim dividend declared at 3.5cps
- Strong balance sheet with net debt of $34.2M
- Focus on sustainable collection centre network expansion and operational efficiencies
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$303 |
Update - Notification of buy-back - PIA
|
26 Feb 2025 9:09AM |
$1.210 |
$1.180 |
fallen by
2.48%
|
|
| Energy Resources of Australia Limited (ERA) ORDINARY FULLY PAID 'A' |
Energy |
$1,013 |
Appendix 3Y - Justin Carey
|
26 Feb 2025 9:09AM |
$0.002 |
$0.003 |
risen by
25%
|
|
| Paladin Energy Ltd (PDN) ORDINARY FULLY PAID |
Energy |
$2,906 |
Appendix 4D and December 2024 Half Year Financial Results
|
26 Feb 2025 9:09AM |
$7.290 |
$7.285 |
fallen by
0.07%
|
|
PDN - Price-sensitive ASX Announcement
Full Release
Key Points
- Paladin Energy Ltd is a significant independent uranium producer.
- The company acquired Fission Uranium Corp. in December 2024.
- The Langer Heinrich Mine produced 1.3 million pounds of U3O8 in the reporting period.
- Revenue from uranium sales increased 100% to $77.25 million.
- The reported loss attributable to members was $4.57 million.
- Paladin is committed to responsible and transparent uranium resource management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$513 |
Appendix 4D and 1H25 financial statements
|
26 Feb 2025 9:09AM |
$3.700 |
$2.610 |
fallen by
29.46%
|
|
ACL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue from ordinary activities rose to $369.2 million.
- Profit attributable to members increased by 136.03% to $11.7 million.
- Basic earnings per share improved to 5.83 cents.
- The half-year financial report was prepared in accordance with AASB 134.
- Independent auditor confirmed the financial report provides a true and fair view.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
